6 All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a varying extent
7 20% of all mediastinal neoplasms 50% of all primary tumors in the anterior compartment 90% of thymic tumors are thymomas
8 Slow-growing tumors Exhibit malignant potential: Local invasion Systemic metastasis without overt cytological features of malignancy More common between ages 40 to 60
9 ~50% - asymptomatic, discovered incidentally on CXR or at autopsy ~30% local symptoms related with pressure or local invasion: SVC sdr., cough, chest pain, dysphonia, dysphagia ~20%- 70% associated with an autoimmiune disease: Myasthenia gravis Pure red cell aplasia Polymyosistis hypogammaglobulnemia
10 Chest CT scan is the imaging procedure of choice Thymic enlargement should be determined because most enlarged thymus glands on CT scan represent a thymoma. CT scan with intravenous contrast dye is preferred to show the relationship between the thymoma and surrounding vascular structures, to define the degree of its vascularity, and to guide the surgeon in removal of a large tumor, possibly involving other mediastinal structures
14 Magnetic resonance imaging (MRI). An MRI uses magnetic fields, not x-rays, to produce detailed images of the body. Positron emission tomography (PET) scan. In a PET scan, radioactive sugar molecules are injected into the body. Cancer cells absorb sugar more quickly than normal cells, so they light up on the PET scan. PET scans are often used to complement information gathered from CT scan, MRI, and physical examination. CT scanning reveals evidence of an anterior mediastinal mass, the PET scan shows a hypermetabolic mass consistent with this location, thereby raising suspicion of malignancy. PET scanning should be added to the armamentarium as an available diagnostic modality to aid in staging and excluding extramediastinal involvement
15 Biopsy: If a patient presents with atypical features or is found to have an invasive tumor and is under consideration for induction therapy, obtaining preoperative biopsy is indicated. The limited anterior mediastinotomy (Chamberlain approach) is the standard approach that typically is performed over the projection of the tumor. A thoracoscopic approach for biopsy also can be used
16 No clear histologic distinction between benign and malignant thymomas exists. The propensity of a thymoma to be malignant is determined by the invasiveness of the thymoma.
18 The preferred approach is a median sternotomy providing adequate exposure of the mediastinal structures and allowing complete removal of the thymus, If the tumor is small and appears readily accessible, perform a total thymectomy with contiguous removal of mediastinal fat. If the tumor is invasive, perform a total thymectomy in addition to en bloc removal of involved pericardium, pleura, lung, phrenic nerve, innominate vein, or superior vena cava. Resect one phrenic nerve; however, if both phrenics are involved, do not resect either nerve, and debulk the area. Clip areas of close margins or residual disease to assist the radiation oncologist in treatment planning
19 Their morphologic heterogeneity has caused much confusion regarding their classification. Several classifications have been proposed to correlate histology and clinical course. Previous studies have shown that the mediastinal invasion as reflected by the staging system of Masaoka negatively affects survival
20 Tumor extent but also grading the tumor could be required to predict prognosis and recurrence pattern which might help to define more precisely the role of adjuvant and neoadjuvant treatments. Therefore, not only staging, the several histologic classifications have been assessed, but they did not help to predict the evolution of thymic tumors after resection
21 WHO Histologic Description Free Survival at 10 years, % A Medullary thymoma 100 AB Mixed thymoma 100 B1 Predominantly cortical thymoma 83 B2 Cortical thymoma 83 B3 Well-differentiated thymic carcinoma 35 C Thymic carcinoma 28 Series of 100 thymomas resected in Japan between 1973 and 2001 using the WHO classification.
22 The prognosis of a person with a thymoma is based on the tumor's gross characteristics at operation, not the histological appearance. Benign tumors are noninvasive and encapsulated. Conversely, malignant tumors are defined by local invasion into the thymic capsule or surrounding tissue. The Masaoka staging system of thymomas is the most commonly accepted system. Preponderance of evidence indicates that all thymomas, except completely encapsulated stage 1 tumors, benefit from adjuvant radiation therapy
23 Relapse after primary therapy for a thymoma may occur after years. Therefore, long-term follow-up probably should continue to be performed throughout the patient's life.
24 Multivariate analysis showed age, gender, myasthenia gravis, and postoperative adjuvant therapy not to be significant predictors of survival after complete resection, whereas the Muller-Hermelink and Masaoka classifications were independent significant predictors for overall (p < 0.05)
27 Uncommon and lethal cancer. Currently no standard treatment. Asbestos exposure is major risk factors.
28 Asbestos belongs to the family of silicate fiber. Include two mineralogical groups: Amphibole and Serpentine.
29 Narrow and straight fibers. Migrate through the lymphatics of pulmonary parenchyma and accumulate in interstitial space and subpleural region. Crocidolite asbestos(blue asbestos)-- The most associate with malignant mesothelioma.
30 Large, curly shaped fiber. do Not travel beyond the major airways. Chrysotile(white asbestos, the only member of Serpentin) -- More associate with lung cancer.
32 Abnormal ECG Sinus tachycardia (42%). Echocardiographic findings. No specific tumor marker. Rise serum hyaluronan. CA-125 (20%).
33 Chest-x ray Variable and related to stage of tumor. Large pleural effusion, pleural thickening, pleural-based mass. Encasement of lung and obliteration of pleural space. Involve pericardium and pericardial effusion. Chest wall invasion, invasion through diaphragm. CT Most accurate noninvasive way to stage. PET scan.
37 Thoracentesis, cytology(positive rate 30-50%). Percutaneous pleural biopsy. Thoracoscopy. Open pleural biopsy. AVOID Exploratory thoracotomy. Bronchoscopy. Meidastinoscopy. Bone scans.
38 An accurate staging system is needed to guide the choice of therapy for patients with mesothelioma and ultimately to assess the results of treatment with different modalities Staging systems The most widely used staging system is the tumor (T), node (N), metastasis (M) staging system that has been adopted by both the International Union Against Cancer (UICC) and the American Joint Committee on Cancer
39 Clinical staging of malignant mesothelioma is performed radiographically in patients with potentially resectable malignant mesothelioma. Although radiographic staging evaluation is warranted, accurate staging is only possible at the time of operation
40 Patient with malignant mesothelioma face a dual problem Control of the locoregional tumor throughout the course of their disease, prevention of distant metastases as late manifestation of their cancer. Choice of treatment Location and extent of he tumor, the general medical condition of patient. Surgery, radiation, chemotherapy, immunotherapy, supportive care.
41 Still the mainstay of treatment. Three operation (1). Extrapleural pneumonectomy. (pleuropneumonectomy) (2). Pleurectomy-decortication. (3). Palliative limited pleurectomy.
42 En bloc resection of pleura, lung, ipsilateral hemidiaphragm, pericardium, Value Controversial. Operative mortality 6-30%. Preoperative CT, lung function, ventilationperfusion scan, cardiac function evaluate.
43 Remove all gross pleural disease, without removing underlying lung. Also remove hemidiaphragm and pericardium.
44 Resection parietal pleura to control pleural effusion. Thoracoscopy and talc poudrage High effective in controlling effusion.
45 The choice of a specific procedure EPP versus P/D is a function of the extent of disease within the thorax and the surgeon s judgement on the ability to achieve a MCR while preserving lung parenchyma. There are no randomized trials that compare EPP versus P/D.
47 Patients with malignant pleural mesothelioma typically present with pulmonary symptoms. Chest imaging typically shows unilateral pleural thickening and pleural effusion. Paraneoplastic syndromes can be associated with pleural mesothelioma, but rarely are the initial manifestation of disease. The diagnosis of malignant mesothelioma requires a tissue sample. The differential diagnosis of malignant pleural mesothelioma includes inflammatory reactions, which can mimic pleural mesothelioma, as well as metastases from other malignancies. Thoracentesis and closed pleural biopsy are the initial procedures in most cases. If this is not diagnostic, surgical intervention is required to obtain an adequate tissue sample.
48 Clinical staging primarily relies upon imaging studies to assess the extent of disease and determine whether or not the patient is a candidate for surgical resection. However, clinical staging often underestimates the extent of disease, and intraoperative staging provides a more reliable assessment of whether or not the patient is a candidate for surgical resection.
What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and
EDUCATION EXHIBIT 105 Malignant Pleural Mesothelioma: Evaluation with CT, MR Imaging, and PET 1 CME FEATURE See accompanying test at http:// www.rsna.org /education /rg_cme.html LEARNING OBJECTIVES FOR
Patient's Guide to Thoracic Cancer The Thoracic Oncology Program consists of an experienced team of nationally recognized cancer specialists experienced in the treatment of: Lung Cancer Tracheal Cancer
Eur Respir J 2010; 35: 479 495 DOI: 10.1183/09031936.00063109 CopyrightßERS Journals Ltd 2010 ERS/ESTS TASK FORCE Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons
Malignant Pleural Mesothelioma NCCN Guidelines for Patients Presented with support from the national law firm of Baron & Budd Also available at NCCN.com About this booklet Its purpose Learning that you
MedSolutions, Inc. Clinical Decision Support Tool Diagnostic Strategies This tool addresses common symptoms and symptom complexes. Imaging requests for patients with atypical symptoms or clinical presentations
BREATHE EASY HOW RADIOLOGY HELPS TO FIND AND FIGHT LUNG DISEASES TABLE OF CONTENTS 3 BREATHE EASY TABLE OF CONTENTS 4 INTRODUCTION: AN OVERVIEW OF CHEST IMAGING 9 CHAPTER 1: Lung imaging: the techniques
28 Radiologic Assessment of Mesothelioma Samuel G. Armato III, Heber MacMahon, Geoffrey R. Oxnard, Charles L. Croteau, and Nicholas J. Vogelzang Imaging plays an essential role in the diagnosis, staging,
& MALIGNANT PLEURAL MESOTHELIOMA TREATED IN CLINIC FOR PULMONARY DISEASES AND TUBERCULOSIS PODHRASTOVI IN TEN-YEAR PERIOD ( FROM 1998 TO 2007 ) Vesna Čukić*, Aida Ustamujić, Vladimir Lovre, Hasan Žutić,
Exhibit A Kane Legal Mesothelioma Handbook Volume No. 1 David Kane, R.Ph., J.D. Professor of Pharmacy Law, Rutgers University Table of Contents Section 1 History of Asbestos...2 Section 2 - What is Mesothelioma?...3
PLEURAL MESOTHELIOMA PLEURAL MESOTHELIOMA By: Domenico Galetta Institute of Oncology Giovanni Paolo II I.R.C.C.S. Oncology Hospital of Bari, Italy Silvia Novello University of Torino, Italy San Luigi Hospital
A Patient s Guide to Mesothelioma What Is Mesothelioma? Causes and Risk Factors Finding a Specialist Treatment Options Legal Decisions Resources cure C a n c e r U p d at e s, R e s e a r c h & E d u c
SCREENING FOR MESOTHELIOMA Current recommendations for screening of patients who have been exposed to significant amounts of asbestos is that screening is not undertaken because there is no effective early
Ministry of Defence Synopsis of Causation Mesothelioma Author: Dr David Jenkins, Medical Author, Medical Text, Edinburgh Validator: Professor Mark Britton, St Peter s Hospital, Chertsey, Surrey September
Case introduction 陳 先 生, 71y/0 96/10/9, Received TURP for BPH at 仁 愛 醫 院, pre-surgery CXR showed an abnormal mass over LUL. 96/10/19 TMUH, He went to Dr. 鍾 OPD for help Abnormal CXR finding Arrange chest
The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name
American Thoracic Society Documents Diagnosis and Initial Management of Nonmalignant Diseases Related to Asbestos This official statement of the American Thoracic Society was adopted by the ATS Board of
Evidence-based Series #7-14-2: Section 1 Surgical Management of Malignant Pleural Mesothelioma: A Clinical Practice Guideline D.E. Maziak, A. Gagliardi, A.E. Haynes, J.A. Mackay, W.K. Evans, and members
KATHERINE M.A. O REILLY, M.D., Southampton General Hospital, Southampton, United Kingdom ANNE MARIE MCLAUGHLIN, M.B., St. Vincent s University Hospital, Dublin, Ireland WILLIAM S. BECKETT, M.D., and PATRICIA
Ann Ist Super Sanità 2009 Vol. 45, No. 2: 147-161 147 Health surveillance for subjects with past exposure to asbestos: from international experience and Italian regional practices to a proposed operational
Standards and datasets for reporting cancers Dataset for the histological reporting of mesothelioma April 2013 Authors Professor Andrew G Nicholson, Royal Brompton Hospital and Harefield NHS Trust Professor
ASBESTOS RELATED LUNG DISEASE Version 2 Final Page 1 Document control Version history Version Date Comments 2 Final 19 January 2007 Signed off by MSCMT 2e (draft) 21 November 2006 Comments from MSCMT incorporated
MALIGNANT PLEURAL MESOTHELIOMA Effective Date: December, 2012 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Malignancies Tumour Team synthesis of currently
Special Section: Cancer in Children & Adolescents Overview The news of a cancer diagnosis is never welcome, but may be even more unexpected and difficult when the disease is diagnosed in a child or adolescent.
3- B ~ E. Asbestos-Related Respiratory Diseases Takumi Kishimoto Deputy-director, Okayama Rosai Hospital, Japan Summary For the pulmonary diseases arising from asbestos there are benign lesions from asbestosis